ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

In the end, BrainStorm Cell Therapeutics’ dalliance with the newly enacted right-to-try law was little more than a publicity stunt. On Tuesday, the small biotech company said it would not offer its experimental stem cell therapy to patients with amyotrophic lateral sclerosis, or ALS, outside of an ongoing Phase 3 clinical trial.